Subject Expert Committee (SEC)

Morepen Laboratories advances Resmetirom development for NASH treatment following SEC approval

Shilpa Medicare secures Subject Expert Committee approval for its novel therapy Nor Ursodeoxycholic Acid, following positive phase…